Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

NCT06170710 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

173

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Anti-PD-1 monoclonal antibody
OTHER: Postoperative CCRT

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences